MLN3897
a CCR1 receptor antagonist; structure in first source
Also Known As:
4-(4-chlorophenyl)-1-(3-(7-(1-hydroxy-1-methylethyl)-11H-10-oxa-1-azadibenzo(a,d)cyclohepten-5-ylidene)propyl)-3,3-dimethylpiperidin-4-ol
Networked: 3
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Brown, Matthew F:
1 article
(01/2010)
|
| 2. | Gladue, Ronald P:
1 article
(01/2010)
|
| 3. | Zwillich, Samuel H:
1 article
(01/2010)
|
| 4. | Chi, Xuedong:
1 article
(12/2009)
|
| 5. | Gerlag, Danielle M:
1 article
(12/2009)
|
| 6. | Karol, Michael:
1 article
(12/2009)
|
| 7. | Leach, Timothy:
1 article
(12/2009)
|
| 8. | Matzkin, Ellen:
1 article
(12/2009)
|
| 9. | Tak, Paul P:
1 article
(12/2009)
|
| 10. | Vergunst, Clarissa E:
1 article
(12/2009)
|
Related Diseases
| 1. | Rheumatoid Arthritis
12/01/2009
- " MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study." 12/01/2009
- " To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). " 01/01/2010
- " Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "
|
| 2. | Chronic Obstructive Pulmonary Disease (COPD)
|
| 3. | Multiple Sclerosis
|
| 4. | Multiple Myeloma
|
|
Related Drugs and Biologics